1. Home
  2. Category
  3. Cancer Type

Melanoma and Skin Cancer

Editorial

What's the Price of a Tan?

Deborah K. Mayer
CJON 2012, 16(4), 337 DOI: 10.1188/12.CJON.337
Growing up, I would use baby oil and iodine and lay out in the sun to get a good tan. And my daughter did what her friends were doing and got a tan at a tanning salon before the prom. Now it is hard to drive by a group of stores without seeing a tanning salon. In the past 30 years, we have seen the...
0
No votes yet
Read this Article
Advanced Practice Nursing Issues

Dermatologic Assessment From a Distance: The Use of Teledermatology in an Outpatient Chemotherapy Infusion Center

Jeanine Gordon
CJON 2012, 16(4), 418-420 DOI: 10.1188/12.CJON.418-420
Treatment-related dermatologic toxicities are common for patients with cancer. Rashes associated with dermatologic toxicities are best treated by a physician who specializes in dermatologic conditions resulting from cancer treatment, but scheduling and travel may present challenges for patients...
0
No votes yet
Read this Article
Online Exclusive Article

Managing Immune-Related Adverse Events to Ipilimumab: A Nurse's Guide

Krista M. Rubin
CJON 2012, 16(2), E69-E75 DOI: 10.1188/12.CJON.E69-E75
Ipilimumab is a U.S. Food and Drug Administration-approved novel T-cell potentiator that improves survival in metastatic melanoma. Ipilimumab blocks cytotoxic T-lymphocyte antigen-4, a negative regulator of the immune response, thus promoting T-cell activation and prolonging a patient's antitumor...
0
No votes yet
Read this Article
Article

Atypical Clinical Response Patterns to Ipilimumab

Blanca Ledezma
Sandra Binder
Omid Hamid
CJON 2011, 15(4), 393-403 DOI: 10.1188/11.CJON.393-403
Patients with advanced melanoma have few treatment options, and survival is poor. However, improved understanding of how the immune system interacts with cancer has led to the development of novel therapies. Ipilimumab is a monoclonal antibody that inhibits cytotoxic T-lymphocyte antigen-4 (CTLA-4...
0
No votes yet
Read this Article
Article

Management of Metastatic Melanoma: Nursing Challenges Today and Tomorrow

Krista Rubin
CJON 2009, 13(1), 81-89 DOI: 10.1188/09.CJON.81-89
Advanced and metastatic melanoma is a devastating and deadly disease.No standard of care has been established to date.As the understanding of the natural history of this disease advances, agents directed at interrupting single and multiple steps in the proliferation, growth, and metastatic...
0
No votes yet
Read this Article

Related e-Books

View More

Questions, Concerns or Requests

We're just a click away for assistance.